FERRO SANOL GYN
MERINAL
Identification
- Active ingredient (INN)
- COMPLEXE DE FER II GLYCINE SULFATE/EQUIVALENT EN FER²+/ACIDE FOLIQUE
- Internal code
- 12 E 108
- Country of Origin
- Algeria
- Pharmaceutical form
- Capsule with Gastro-resistant Granules
- Prescription List
- OTC
- Packaging
- b/50
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Description
A medication used to treat low levels of iron in the body.
Indications
Used in preventing and treating iron-deficiency anemia.
Pharmacodynamics
The major activity of supplemental iron is in the prevention and treatment of iron deficiency anemia.
Iron has putative immune-enhancing, anticarcinogenic and cognition-enhancing activities.
Mechanism of Action
Iron is necessary for the production of hemoglobin.
Iron-deficiency can lead to decreased production of hemoglobin and a microcytic, hypochromic anemia.
Transferrin receptor protein 1 Not Available Humans U Egl nine homolog 1 Not Available Humans U Histone deacetylase 8 Not Available Humans U Alpha-hemoglobin-stabilizing protein Not Available Humans U Hemoglobin subunit alpha Not Available Humans U Frataxin, mitochondrial Not Available Humans U Ferritin heavy chain Not Available Humans U Flap endonuclease 1 Not Available Humans U Endonuclease 8-like 1 Not Available Humans U Endonuclease 8-like 2 Not Available Humans U DNA polymerase beta Not Available Humans U Ceruloplasmin Not Available Humans U Serotransferrin Not Available Humans.
Absorption
The efficiency of absorption depends on the salt form, the amount administered, the dosing regimen and the size of iron stores.
Subjects with normal iron stores absorb 10% to 35% of an iron dose.
Those who are iron deficient may absorb up to 95% of an iron dose.
Adverse Effects
Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.
Toxicity
Acute iron overdosage can be divided into four stages.
In the first stage, which occurs up to six hours after ingestion, the principal symptoms are vomiting and diarrhea.
Other symptoms include hypotension, tachycardia and CNS depression ranging from lethargy to coma.
The second phase may occur at 6-24 hours after ingestion and is characterized by a temporary remission.
In the third phase, gastrointestinal symptoms recur accompanied by shock, metabolic acidosis, coma, hepatic necrosis and jaundice, hypoglycemia, renal failure and pulmonary edema.
The fourth phase may occur several weeks after ingestion and is characterized by gastrointestinal obstruction and liver damage.
In a young child, 75 milligrams per kilogram is considered extremely dangerous.
A dose of 30 milligrams per kilogram can lead to symptoms of toxicity.
Estimates of a lethal dosage range from 180 milligrams per kilogram and upwards.
A peak serum iron concentration of five micrograms or more per ml is associated with moderate to severe poisoning in many.